Medical Board Beefs up Burzynski Complaint
The Texas Medical Board has enhanced its complaints against controversial Houston doctor (for loss of a better word) Stanislaw Burzynski, beefing up an eight-page complaint filed in December 2013 to a whopping 200, the Chron reports.
Filed July 9, the amended complaint came on the FDA's bewildering decision to lift a suspension on Burzynski's clinical trials involving an alleged cancer-fighting drug he calls antineoplastons. The FDA had partially suspended trials after the 2012 death of a six-year-old patient involved in one of the studies; the federal agency had also accused him of inaccurately reporting patient outcomes and failing to obtain some patients' informed consent.
The amended complaint alleges that Burzynski "created a medical practice model based on marketing his proprietary anti-cancer drugs to patients without adequate measures for patient safety and therapeutic value. [Burzynski] misled patients knowingly by promoting these drugs as an attraction to bring to his medical practice when [he] was aware that he could not legally include most of those patients in FDA-approved...clinical trials."
The board also accused Burzynski of misleading "patients into paying funds as a retainer prior to receiving any evaluation, diagnosis, or treatment."
If an administrative law judge agrees with the board's contentions that Burzynski violated state health and safety statutes, he could potentially lose his license.
Burzynski's lawyer, Richard Jaffe, told the Chron that the latest allegations were "outrageous" and "crazy," and the story quoted him as saying, "one way or another, this is going to be the last case."
"We'll let the judge decide whether Dr. Burzynski is helping people or not," Jaffe told the paper.
According to the Chron, "the matter is not expected to come before the State Office of Administrative Hearings until sometime in 2015."
Yeah, we'd hate for them to rush things. It's only dying patients' lives at stake.
Get the Weekly Newsletter
Our weekly feature stories, movie reviews, calendar picks and more - minus the newsprint and sent directly to your inbox.